Target intelligence / Profile preview

D-alanyl-D-alanine peptide terminus (D-Ala-D-Ala)

Target
D-Ala-D-Ala
Molecular classification
Peptide, Cell wall component, Other
01

Overview

The D-alanyl-D-alanine peptide terminus is a carboxy-terminal dipeptide motif found at the end of the stem pentapeptide in peptidoglycan precursors of bacterial cell walls. It is a key structural element essential for peptidoglycan cross-linking during bacterial cell wall biosynthesis. This motif acts as a substrate for transpeptidase enzymes (penicillin-binding proteins) and is the principal binding site for clinically important antibiotic classes such as vancomycin, which binds the terminus and sterically blocks cell wall cross-linking, and β-lactam antibiotics, which target the transpeptidase active site. Modifications of this terminus, such as substitution with D-alanyl-D-lactate, confer high resistance to glycopeptide antibiotics. The D-Ala-D-Ala terminus therefore remains a validated antimicrobial drug target and has no mammalian equivalent, making it highly specific for selective disruption of bacterial pathogens[1][4][6][8].

Other names
D-Ala-D-AlaD-alanyl-D-alanine dipeptidePeptidoglycan precursor terminus
02

Mechanism of action

Vancomycin: Binds directly to the D-Ala-D-Ala terminus, blocking access by transpeptidases and inhibiting cell wall synthesis[1][6]. β-lactam antibiotics (including penicillin): Inhibit penicillin-binding proteins that use the D-Ala-D-Ala motif as a substrate, preventing cross-linking of peptidoglycan strands critical for bacterial cell wall integrity[1][4].

03

Biological functions

Cell wall synthesisSubstrate for transpeptidasesPeptidoglycan cross-linking
04

Disease associations

Infection
05

Safety considerations

Null (no direct safety concerns are attributed to this target itself, but clinical resistance or off-target effects from antibiotic therapy are relevant[1])
06

Interacting drugs

Vancomycin

2 more in the full profile.

07

Biomarkers

Null (no specific patient selection or efficacy biomarkers for this terminus, though resistance mechanisms such as the VanX dipeptidase or D-Ala-D-Lactate substitution are used for diagnostic purposes in resistant strains[6])

Beyond the preview

Go deeper on D-alanyl-D-alanine peptide terminus (D-Ala-D-Ala).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on D-alanyl-D-alanine peptide terminus (D-Ala-D-Ala).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call